Skip to main content
Clinical Trials/NCT04280354
NCT04280354
Terminated
Not Applicable

Prospective Study to Discover New Biomarkers for Early Detection of Sepsis and Prediction of Sepsis-related Mortality in Patients With Severe Community Acquired Pneumonia (sCAP)

University Hospital, Basel, Switzerland15 sites in 1 country3 target enrollmentFebruary 16, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
University Hospital, Basel, Switzerland
Enrollment
3
Locations
15
Primary Endpoint
Detection of sepsis
Status
Terminated
Last Updated
last year

Overview

Brief Summary

This multi-center observational case-control study in Intensive Care Unit (ICU) patients is to identify novel biomarkers allowing to recognize severe community acquired pneumonia (sCAP) -associated sepsis at an earlier stage and predict sepsis-related mortality. Patients with sCAP (cases) will be profoundly characterized over time regarding the development of sepsis and compared with control patients. The mechanisms and influencing factors on the clinical course will be explored with most modern -omics technologies allowing a detailed characterisation. These data will be analysed using machine learning algorithms and multi-dimensional mathematical models.

Registry
clinicaltrials.gov
Start Date
February 16, 2022
End Date
July 31, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
University Hospital, Basel, Switzerland
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Admission to the ICU of one of the participating centers.
  • Cases: severe community acquired pneumonia with requirement for ICU admission.
  • Controls: Clinical phenotype of inflammation not due to suspected sepsis In addition, control patients will be patients with fever \>38°C, CRP \>100mg/L, no infection focus expected in ≥ 24h.
  • All required sample types can most likely be collected within the first 24h visits.
  • Expected ICU stay of more than 24h.

Exclusion Criteria

  • Admission to the hospital within the prior 14 days.
  • Patients with psychosis
  • Evidence of a hospital acquired pneumonia.
  • One of the following respiratory conditions: Acute exacerbation of chronic obstructive pulmonary disease (COPD) or bronchiectasis, acute severe asthma, aspiration pneumonia, tuberculosis, clinical suspected viral pneumonia without bacterial infection, cardiogenic pulmonary oedema.
  • Patients with an acute respiratory distress Syndrome (ARDS).
  • Patient which can be managed as outpatients and do not require an ICU.
  • Patient where a transmission to another institution is likely within the next 24h.
  • Documented rejection of the general consent or participation to research in general.
  • Patients with a palliative situation and a life expectancy due to other diseases (e.g. progressed cancer) less than 28 days.

Outcomes

Primary Outcomes

Detection of sepsis

Time Frame: within 7 days after study inclusion

Sepsis detection based on new discovered digital biomarkers will be compared to classical sepsis-3 criteria (with an increase of the sequential organ failure assessment (SOFA) score of 2 or larger score points).

Time to sepsis detection (minutes after Intensive Care Unit (ICU) admission)

Time Frame: within 7 days after study inclusion

Time to sepsis detection (minutes after ICU admission) based on machine learning

Sepsis related mortality

Time Frame: within 7 days after study inclusion

Prediction of sepsis related mortality (with \>80% sensitivity and specificity at least 24h prior to event)

Study Sites (15)

Loading locations...

Similar Trials